Schaeffer, Eva http://orcid.org/0000-0002-0792-4383
Vaterrodt, Thomas
Zaunbrecher, Laura
Liepelt-Scarfone, Inga
Emmert, Kirsten
Roeben, Benjamin
Elshehabi, Morad
Hansen, Clint
Becker, Sara
Nussbaum, Susanne
Busch, Jan-Hinrich
Synofzik, Matthis
Berg, Daniela
Maetzler, Walter
Funding for this research was provided by:
Janssen Research and Development
Medizinischen Fakultät, Eberhard Karls Universität Tübingen
Projekt DEAL
Article History
Received: 19 December 2020
Revised: 18 January 2021
Accepted: 19 January 2021
First Online: 5 February 2021
Compliance with ethical standards
:
: E. Schaeffer received intramural research funding from the University of Kiel and speaker’s honoraria from Bayer Vital GmbH and Novartis, outside the submitted work. T. Vaterrodt, L. Zaunbrecher, K. Emmert, M. Elsehabi, B. Roeben, C. Hansen, S. Becker, S. Nussbaum and J-H. Busch have nothing to declare. I. Liepelt-Scarfone received an unrestricted research grant from Johnson & Johnson to conduct the ABC-PD study, and grants from the International Parkinson Fonds GmbH IPO, European Commission Horizon 2020, National Center of Excellence in Research, Luxembourg National Research Fund and Michael J Fox Foundation. M. Synofzik received Consultancy Honoraria von Actelion Pharmaceuticals, outside the submitted work. D. Berg reports grants from Janssen Pharmaceutica, grants from the Damp foundation, grants from the German Parkinson’s Disease Association (dPV), grants from BMWi, grants from BMBF, grants from the Parkinson Fonds Deutschland GmbH, grants and speaker’s honoraria from and consultancy honoraria of UCB Pharma GmbH, grants and speaker’s honoraria from TEVA Pharma GmbH, grants from and consultancies for Novartis Pharma GmbH, grants and speaker’s honoraria from and consultancy honoraria of Lundbeck, speaker’s honoraria from and consultancy honoraria for BIAL, speaker’s honoraria from and consultancy honoraria for Biogen, honoraria from Bayer and Zambon outside the submitted work. W. Maetzler receives or received funding from the European Union, the German Federal Ministry of Education of Research, Neuroalliance, Lundbeck and Janssen. He received speaker honoraria from Abbvie, Bayer, GlaxoSmithKline, Licher MT, Pharma, Takeda and UCB, was invited to Advisory Boards of Abbvie, Biogen, Lundbeck and Market Access & Pricing Strategy GmbH, and is an advisory board member of the Critical Path for Parkinson’s Consortium. He serves as the co-chair of the MDS Technology Task Force.
: All procedures performed in the above mentioned studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Training-PD and ABC-PD study were approved by the ethics committee of the Medical Faculty of the University of Tübingen (112/2015BO2 and 686/2013BO1). For the Saarbrücken PD survey no ethical approval was needed (confirmed by the Ethic Commission of the State Chamber of Medicine, Saarland).